Accelerating Biotech Breakthroughs

Buy tokens

Token Sale Round 4 ends in:


20 622

2 083 568 2 083 568
Buy tokens

Genexi accelerates the transition of cutting-edge biotech projects from research to the market

Token holders

Support the international community to fight counterfeit drugs with digital tools


The development of biotechnology holds tremendous promises for the developing world


We pledge to provide regulatory, advisory and research expertise to improve the quality of your life

Help us build the community of biotech and digital health enthusiasts


Transactions via Smart Contracts

  • Efficiency. Eliminate a vast chain of middlemen
  • Speed. No need to process documents manually
  • Security. The highest level of data encryption
  • Trust. Absolute confidence in their execution
  • Transparency. Fully visible T&Cs to all relevant parties

Blockchain Solution for Supply Chain Quality Management

  • Effective fraud detection process
  • Fast access to the supply chain data
  • Full traceability and reduced inherent risks
  • A link between physical and information flows
  • Information sharing between the different stakeholders

Biotech Vendor

  • Focus on the target audience
  • Mitigation of supplier risks
  • Protection of your brand
  • Reduced marketing expenses
  • Increased on-boarding speed
  • Optimised performance

Token GEN

  • Right for specific access to the platform
  • Medium of exchange within the whole ecosystem
  • Reward for your loyalty via bonus programs
  • Transfer of value between distribution chain partners

Global Healthcare Industry Revenue

Growth Rate Forecast: 4.81%

2017 - $1 768 bn.

2018 — $1 853 bn.

Revenue Forecast by Sector

& Biotechnology

Growth Rate: 4.29%

2017 - $1 195 bn.

2018 — $1 246 bn.


Growth Rate: 5.18%

2017 — $371 bn.

2018 — $390 bn.


Growth Rate: 6.37%

2017 — $108 bn.

2018 — $115 bn.

Healthcare IT

Growth Rate: 9.99%

2017 — $65 bn.

2018 — $72 bn.

Medical Imaging

Growth Rate: 4.42%

2017 — $29 bn.

2018 — $31 bn.

Our Insight

Biotechnology involves transformative technologies for medicine, environment and agriculture. The use of living systems and organisms to make or develop products has increased dramatically over the recent years.

An increasing demand for biotechnology-based diagnostics and therapeutics solutions such as DNA sequencing, tissue engineering and regeneration, cell-based assay promotes funding to support R&D and new product development endeavours.

Growth Opportunities

2017 was a record year for biotech investments. VC funding for digital health accounted for nearly $4.5 billion which is approximately 109% up in comparison with 2016.

According to our estimates, the world biotechnology market value will cross $2 trillion in 2018 with 67% of manufacturers revenue coming from the sales of biotech and pharmaceutical products.

We expect the global biotech industry to register a stable annual growth of around 4.9% during the next 5 years.

Key Biotechnology Areas

DNA Sequencing

Genome analysis cost has significantly reduced because of the emergence of second and third generation sequencing technologies (NGS). As a whole genome scanning cost falls the personalised medicine grows, a new understanding of the genetic variation of individuals is appeared. Moreover, unidentified vast regions of DNA now are clear and unlocked.

Stem Cell Therapy

Medical scientists and drug developers have tremendous opportunities to test drugs in the lab as they see how stem cells are able to grow into any of the body’s specialised cells. However, their major goal and perspective is to rise to an era of regenerative medicine where life-altering injuries and deadly diseases are not just treated, but cured.

Gene Therapy

Commonly, the basic cure for a specific disease is when drugs interact by binding with proteins. Some clinical methods solves this problem by acting directly on genes that are responsible for producing the deleterious protein. For accomplishing this there are number of technologies that introduce a gene through a viral vector, RNAi, antisense or use so-called zinc finger proteins.


MicroRNA is a new way of diagnosing and treating disease. MicroRNAs prevents the translation of messenger RNA into proteins by breaking down of messenger RNA. The absence or presence of specific microRNAs in various cells is held by specific human diseases, including cancer, viral infection, metabolic disorders and inflammatory disease.

Tissue Engineering

Growing prevalence of chronic diseases heightening the demand for new drug development is one of the key factors of segment growth during the next 5-year period. The combination of biotechnology and pharmaceutical results in the development of effective and advanced therapies used to treat many life threatening diseases.

Implantable Sensors

Intelligent and implantable devices serve medicine with monitoring the health of an individual and, in some cases, alert or even respond to changing conditions within the body.

Vaccine Technology

Biotechnology gives good grounds for expecting cheaper and safer vaccines. Alternatively DNA vaccines use a piece of genetic code for a pathogen instead of using a weakened or killed virus use a piece of genetic code for a pathogen. Traditional methods involve using eggs to grow vaccines. DNA vaccines can be made cardinally quicker and production is more bigger and innovative.

Synthetic Biology

Synthetic biology includes a construction of DNA as a basis for building organisms that can perform specific tasks. It is a major part in developing new biofuels that can break the world’s addiction to petroleum. This sphere draws a great attention for its potential in providing cleaner and renewable sources of fuel. Thus it is changing everything from the way drugs are made to the way industrial goods are manufactured.

Systems Biology

Systems biology focuses on understanding the interaction between a series of genes and their interactions with proteins. Advances in computing, the falling cost of genetic analysis, and other technological advances made this data-intensive approach possible.

Cancer Immuno Therapy

Accelerated breakthroughs in Adoptive T-cell therapies will contribute to the growth of immuno-oncology market during the next 10 years.

Grant Portfolio

Bacteriorhodopsin is a photosensitive protein of purple membranes of Halobacterium salinarum microorganisms living in salt lakes, where the salt concentration is 6 times higher than in the seawater.

Application areas:

Pharmaceutics and cosmetology

Treatment of psoriasis, asthma, conjunctiviti


Plant growth


of biocomputers


The RESTET skin regeneration system is the flagship project focused on the research and development of next generation medicines based on bacteriorhodopsin - one of the most promising means of fighting against diseases such as psoriasis, atopic dermatitis, neurodermatitis and acne. RESTET is a unique breakthrough in the field of molecular biocosmetology and has no side effects. The methods of treatment are effective for any age, sex, duration of skin lesions. The unique process of the synthesis of bacteriorhodopsin has been patented in different countries, including Germany, France, China, Iran and South Korea.


  • Transparency in the use of funds
  • Instant custody without intermediaries
  • Decentralised process of funding technology
  • International reach and flexibility
  • Early contributors will have more liquidity in early stage companies

Genexi Foundation

  • Use blockchain technologies to publish funding and grant information in real time
  • Promote and support Genexi Ecosystem
  • Bring decentralised protocols and digital tools into the biotech field
  • Empower researchers and entrepreneurs to implement their innovative ideas
  • Build a global community of biotech enthusiasts
ManufacturersEcosystemCustomersBlockchainSmart contract

Token GEN features additional cashback and discount provision services

Total Supply12 000 000 000 GEN

Hard Cap70 000 000 $

Soft Cap20 000 000 $

Token price0.01 $

Pre-Sale Round01.05 - 31.0520%
Token Sale Round 101.06 – 14.0617%
Token Sale Round 215.06 – 05.079%
Token Sale Round 306.07 – 26.075%
Token Sale Round 427.07 – 31.082%

Use of




Primary Scientific and Medical Research

Q1 2017

GENEXI Establishment

Q3 2017

Ecosystem and Platform Development

Q1 2018

Low Level Design Launch

Q2 2018

Foundation Establishment

Q3 2018


Q3 2018

Ecosystem Alpha Version Testing

Q4 2018

Smart-Contract Development and Testing. Grant Application Program Launch

H1 2019

Ecosystem Complete Version Launch

H2 2019

Official Public GENEXI Accelerator Report

2020 onwards

Further Ecosystem Development and Scaling

Advisors & Team

Roel Wolfert


More than 20 years of international experience on business and technology in retail and transactional banking, payments and bank cards, retailing, management consulting, IT and venture capital. Holds MSc in Economics from Maastricht University and an executive degree in innovation from the Haas School of Business at UC Berkeley. He is Chief Operating Officer at Qoin, where he focuses on policy, monetary design, legal advice and tokenomics development. Roel is an external advisor to KICKICO and Bancor Network projects.

Roel Wolfert


More than 20 years of international experience on business and technology in retail and transactional banking, payments and bank cards, retailing, management consulting, IT and venture capital. Holds MSc in Economics from Maastricht University and an executive degree in innovation from the Haas School of Business at UC Berkeley. He is Chief Operating Officer at Qoin, where he focuses on policy, monetary design, legal advice and tokenomics development. Roel is an external advisor to KICKICO and Bancor Network projects.

Oliver Bussmann


Oliver is a globally recognised technology thought leader and driver of large-scale transformation at multinational organizations. The Founder and CEO of Bussmann Advisory AG, he advises enterprises and start-ups looking to stay ahead of the digital disruption curve. He also holds important mandates in industry associations, including as President of the Swiss Crypto Valley Association, Global Ambassador for UK-based Innovate Finance and as a Board Member of Identity 2020. From 2013 to 2016 Bussmann was Group Chief Information Officer of UBS, where he successfully led a major IT transformation effort, instituted a new group-wide innovation framework and established UBS as a pioneer in the development of blockchain for use in financial services. Prior to joining UBS Bussmann was Global Chief Information Officer at SAP, where he also spearheaded significant technological transformation, and before that CIO for North America & Mexico at Allianz. Previous roles have included executive positions at Deutsche Bank and IBM. Bussmann's achievements have been widely recognized. He was named COO/CTO of the year by Financial News/The Wall Street Journal, European CIO of the Year by INSEAD/CIONET, received the Elite 8 Award, which is given to the most innovative leaders in technology working in capital markets by Wall Street & Technology Magazine, and has twice been included on the Financial News "FinTech 40" list of innovators shaping the future of finance.

Malcolm Tan


Malcolm Tan is an established Singaporean lawyer-entrepreneur with extensive experience in the construction, telecommunications, engineering, retail, IT, and financial industries. Trained as a lawyer, Malcolm is also skilled in litigation, corporate law, and mergers and acquisitions. He previously held legal counsel positions in both global and regional capacities across the Asia-Pacific region, MENA, and North America. In addition to owning and running a diverse suite of companies, including the BlueSky Group which owns back-office solution provider ActivBM, Malcolm has been involved in the corporate advisory and corporate finance field, in deals from angel to VC and PE, and also Pre-IPO and IPO deals.

Anti Danilevski


As a founder of KICKICO platform, he leads the biggest Russian crowdfunding community as well as other online communities. Anti has been involved in the blockchain community since 2014 and brings his 11 years of experience in crowdfunding, online community-building and ICO matters into our project.

Richard O'Rourke


Richard started his career as an R&D engineer in the electronics industry in Taiwan and from there moved into fuel cell research in Switzerland. In 2000 he founded and ran the software company KineMatik, a company providing IT solutions to the life sciences and biotech sector, producing software for R&D management in high-tech manufacturing, and pioneering the world’s first integrated program and portfolio management and knowledge management system, the Collaborative eR&D platform eNovator. Richard’s postgraduate qualifications include an MBA (Warwick Business School), M.Sc. (London School of Economics & Political Science), and M.Eng.Sc. (University College Cork). His undergradtuate degree is in industrial chemistry (University of Limerick).

Manuel Rimarachin


Manuel is the regional representative of several ICO projects in Latin America. He began his career in exporting of medical equipment at Equipos Medicos S.A. In recent years, he has become an active member in the crypto community and currently acts as an advisor on the implementation of blocking technology into the public sector of Peru's economy. Manuel is an external advisor for Arbidex, an integrated crypto exchange platform and a founder of P2P block platform GAPMONEY. Holds an international MBA degree from the Peoples' Friendship University of Russia.

Katrina Arden


A founder of Blockchain Law Group, she is a licensed attorney in the USA and in the Russian Federation. She has extensive experience handling various domestic and international issues, including tax compliance and security regulations, structuring international transactions and working on the multimillion dollar lawsuits involving securities fraud.

For certain large token purchases, Genexi is able to use escrow services provided by Blockchain Law Group. Use of escrow is optional and does not apply to regular purchases. Escrow may be available upon request only. A separate escrow agreement is required.

Aleksei Zheliaskov

Founder, CEO

President of JFSC Atlant and a founder of Genexi with over 12 years of professional experience in investment management. Alexey is a serial entrepreneur who has built multiple successful companies in financial and real estate sector. His current focus lies within venture capital business, where he encourages innovation and facilitates entrepreneurship providing both his management and marketing expertise to young entrepreneurs. He seeks to make investments that solve critical social and environmental issues.

Roman Gilvanov

Managing Director

Prior to joining Genexi, Roman acted as CEO of IronFX Russia – one of the largest European FX brokerages with more than 80 branch offices around the world. Throughout his career, Roman held project manager positions in various IT start-ups, managing 15 local teams on three continents.

Sergey Tiurin

Head of Medical Research

Having more than 35 years of medical experience, he is an author of multiple research papers on topics including bioorganic and protein chemistry. His career started in 1982 at State Research Institute of Genetics and Selection of Industrial Microorganisms of the National Research Centre, where he studied the chemical structure of the bendotoxin protein. After the graduation he started a project on biopreparation of bendotoxin with extended spectrum of insecticidal activity, successfully collaborating with the US Department of Agriculture. In 2008, he founded an innovative company BIOS whose main purpose was to create a new product on the basis of bacteriorhodopsin protein, which resulted in the development of a new highly effective medicine to treat skin diseases.

Alexey Nosikov

Head of Operations

Alexey is Head of Operations of Genexi’s Moscow Office. He was previously Head of Strategy at Connectius, where he was in charge of implementing and scaling social side of the business. Connecticus was designed to provide a SaaS-solution for existing e-commerce and digital marketplaces based on blockchain technology.

Andrew Marcus

Head of Strategy

Prior to joining Genexi, Andrew worked at the top NY law firms as a corporate lawyer and then made a successful career as an investment banker within leading PE funds in London, Moscow and Delhi. He specialised in M&A, capital markets, business structuring and strategy.

Bogdan Stepanov

Head of Business Development

Before joining Genexi, Bogdan was with Union Bancaire Privée – Swiss private bank specialised in alternative investments, institutional asset management, and private wealth management. Bogdan has also been involved in the hedge fund industry since 2014, when he joined Toscafund as their research analyst. Holds a BSc (Hons) in Economics from Queen Mary University of London.

Anton Sklovets

Head of Research

15 years of professional experience in trading biotech equities in global capital markets. His daily focus is research and managing the Genexi quantitative team. Prior to joining the team, he worked for the leading Russian pharmaceutical companies where he was responsible for the investment side of business. Graduated the Financial University under the Government of the Russian Federation and holds MSc in Finance.

Daria Goriychuk

Head of HR

Daria is an experienced HR professional. She implements modern HR strategies and manages internal operations, supporting top management with the provision of personal advices and evaluations, playing a key role in talent acquisition and team building.

Aleksei Khokhlov


Alexey has more than 15 years experience in the implementation of IT projects of different focus: CRM systems; in-house systems for insurance companies, retailers and autodealers; web sites, mobile applications, Blockchain projects, and others. Alexey focused on research in the Blockchain technologies, modeling of business processes and data analysis.

Alexander Novoselov

Biotech Analyst

Alexander is a Director of the Moscow Society of Dermatologists. He joined Genexi in 2016, following five years with Russian Dermatology Academic Research Centre and over a decade working for global health, development and public sector organisations. Holds a Masters degree in Medicine.

Maxim Khotimchenko

Biotech Expert

More than 20 years experinece in experimental pharmacology, drug discovery and development. Author of multiple research papers devoted to development of the novel pharmaceutical purposed for treatment of neuodegenrative diseases, malignant tumors, environmental dieorders as well as creation of effective targeted drug dellivery systems. Author of 12 patents for production and use of the new phamacologically actve compounds. Head of numerous R&D projects in Far Eastern Federal University (Russia) and University of California San Diego (California, U.S.A.). Co-founder and CEO of the innovative research and manufacturing companies «Vostokpharm» (Vladivostok, Russia), «Vostokpham Innovations» (Vladivostok Russia, Skolkovo resident), «TaigaSea, LLC (Florida, U.S.A.). Director of Department of Parmacy and Pharmacology in School of Beomedicine in Far Eastern Federal Univeristy.

Anton Nizhenkov

Investment Analyst

Anton became part of Genexi in October 2016 and oversees evidence generation, appraisal and evaluations of grants and programme investments. His professional expertise encompasses portfolio level evaluation, assessing the impact of policy and advocacy investments, transparency and accountability. Holds qualification certificates of financial market specialist 1.0 and 5.0.

Dennis Sarkar

Ecosystem Developer

Prior to his role at Genexi, Dennis was the Senior Account Manager at KICKICO managing key strategic projects and supporting ICO research department with ad-hoc duties. Due to his corporate finance background, his main focus within Genexi is geared towards the project structuring and development of its value drivers. Dennis holds a Bachelor of Arts degree in Economics from De Anza College, California.

Jacques Miabouna

Strategy Consultant

Experienced professional in marketing and sales, worked for several international companies including the UK’s leading charity – The Prince’s Trust. Jacques has been engaged in implementing company wide and departmental transformation activities as well as improving internal process effectiveness.

Vladimir Stark

Head of Marketing

Vladimir has more than 12 years of experience in strategy and digital marketing. As a founder of Digital V&R Group, he is leveraging next gen marketing technologies to solve key issues and deliver more relevant content. Given the current industry challenges related to the rules and regulation around how ICOs could present information on their websites, he seeks for ways to provide a more useful experience to both investors and members of the crypto community. Vladimir has established himself as a particularly perceptive pundit on the matters of marketing and public relations in the global markets.

Anastasia Verbitskaya


Experienced professional in digital marketing and social networks strategy with the focus on ICO projects. Anastasia is responsible for social media accounts growth and web planning & development projects.

Denis Baldakov

Community Manager

Being a first-class specialist in digital marketing, Dennis applies his knowledge in marketing and ICO focused on Spanish-speaking countries and communities in Latin America. Graduated from US3M (Madrid), Faculty of Business Management.

Artem Targosh

Community Manager

Artem is responsible for content creation, social media marketing, communications and marketing strategy within the team. Holds a BSc in Industrial Economics from Moscow State University of Technology, Design, and Art.

Stepan Razenkov

Business Analyst

Stepan focused on structuring of the business domain within the project. His core responsibilities include engagement with developers on production support and projects tasks, as well as requirement gathering and execution of IT projects related to manufacturing. Went to read Economics and Finance at the University of York.

Anna Rafaelli

Chief Editor

A vibrant and energetic journalist, who published multiple articles on the relation of biotech and blockchain technology. Anna’s proficiency in modern languages distinguishes her writing as both profound, witty and appealing for experts and social elites. Holds a MSc in Journalism and Modern languages from Moscow State University, fluent in English, French, Spanish and Italian.

Anna Fursova

PR Manager

More than 5 years of professional experience in communication agencies. Anna coordinates public relations activities, together with developing a holistic media promotion strategy, seeking high-level placements in print, broadcast and online media. She is also responsible for selecting and monitoring high-profile exhibitions and international conferences.

Margarita Ilina

PR Manager

Margarita coordinates public relation activities and oversees our media promotion strategy. Prior to joining GENEXI, she spent 3 years with PR agencies in China and the UAE.

Egor Stepanov

Head of IT

Egor previously worked at the Skolkovo Innovation Center, commonly known as the Russian Silicon Valley, as a full-stack developer.

Alexander Abarevich

Technical Support Lead

Alexander is an Apple certified professional. He is a highly qualified specialist with more than 7 years of professional experience in IT industry. Alexander seeks ways to automate internal processes in order to improve efficiency.


13 July 2018

GENEXI Announces Launch of Restet Production

01 July 2018

GENEXI Welcomes Oliver Bussmann To Advisory Board

20 June 2018

London Calling | GENEXI Attends BAIConf 2018

03 June 2018

Meet GENEXI’s New Advisors: Richard O’Rourke & Manuel Rimarachin Dias

22 May 2018

Finwise Summit Tokyo 2018 - GENEXI Insight

18 April 2018

World Blockchain Forum — Investments & ICOs — Dubai

25 March 2018

Global Blockchain Summit Sochi 2018 - A word from our CEO

10 March 2018

Blockchain Leadership Summit | March 9th | Zurich, Switzerland

07 February 2018

GENEXI at Blockchain Economic Forum 2018 in Singapore

14 January 2018

GENEXI - The Finwise Summit Macau 2018

GENEXI Announces Launch of Restet Production

GENEXI Biotech Accelerator has announced the launch of production of their first granted project - RESTET, a skin regeneration system based on the retinal protein bacteriorhodopsin. With the help of grant funds received through GENEXI, the RESTET team was able to build a world-class research lab where they apply their technical know-how to obtain bacteriorhodopsin and produce the RESTET skin regeneration product line. According to GENEXI CEO Aleksei Zheliaskov, RESTET is a unique breakthrough in the field of microbiology and biotechnology, which will become one of the most effective remedies for treatment of skin conditions such as psoriasis, skin dermatitis and acne.

Read the full article

GENEXI Welcomes Oliver Bussmann To Advisory Board

GENEXI Welcomes Oliver Bussmann To Advisory Board June has been another busy and rewarding month for GENEXI with the appointment of new advisors joining GENEXI Foundation. Please welcome a globally recognized technology thought-leader and driver of large-scale transformation at multinational organizations — Oliver Bussmann. The Founder and CEO of Bussmann Advisory AG, Oliver advises enterprises and startups looking to stay ahead of the digital disruption curve. His strengths lie in bringing people together throughout an organization to reach agreement on a desired future state…

Read the full article

London Calling | GENEXI Attends BAIConf 2018

Blockchain Alternative Investment Conference and Exhibition, one of London’s best and most central conference venues, took place on 18–19 June at 8 Northumberland. BAIConf proved to be a resounding success in terms of bringing together the leading fund managers in cryptocurrencies, CEOs of successful ICOs from 2017 and 2018, institutions and private investors responsible for over US$750 billion of assets under management. Global institutional investors conclude for a reason that Bitcoin and other cryptocurrencies are an emerging asset class with real challenges to achieving their full potential…

Read the full article

Meet GENEXI's New Advisors: Richard O'Rourke & Manuel Rimarachin Dias

Often businesses require assistance as they make crucial decisions that affect their direction. Experienced advisors can bring the insight business owners need. June 2018, GENEXI is proud to announce new advisors joining the team: Richard O'Rourke and Manuel Rimarachin Dias. GENEXI’s culture is a standout in the world of business and marketing planning, rewarding forward thinking and creativity. Our advisors are our greatest success – we say it often and with good reason. The company instils confidence in our employees and their external teammates, always inspiring one another to find a way forward and master their motivation. We foster a culture of innovation and leadership bringing in the right people to continue develop those values further.

Read the full article

Finwise Summit Tokyo 2018 - GENEXI Insight

2018 FINWISE Tokyo was held in Tokyo Japan on May 21-22. FINWISE Summit is one of the most influential blockchain events in the world which aims to strengthen the communication among blockchain- related practitioners and encourage the development of global financial technologies. GENEXI Ecosystem Developer Dennis Sarkar was invited as a speaker to announce GENEXI blockchain platform and fundraising campaign that promotes the culture of innovations, as well as embedding the blockchain into biotechnology.

Read the full article

World Blockchain Forum — Investments & ICOs — Dubai

The World Blockchain Forum, Investment & ICOs was held on 16 -17 April, 2018 in Dubai. Major market players joined the leaders of several countries, economic pioneers and enterprising investors hailing from all corners of the world in discussing the future of the financial world. According to GENEXI co-founder and CEO Alexey Zhelyaskov, one of the conference's primary objectives was to understand the strategic tasks of blockchain globalization within the context of rapidly changing economic conditions.

Read the full article

CEO on blockchain and the real sector at the Global Blockchain Summit 2018 in Sochi

Sochi played host to the Global Blockchain Summit 2018, an international event dedicated to blockchain technology and cryptocurrencies, on 24 March. The program included reports on the following set of pressing issues: the use of blockchain and its future, ICOs, altcoin prospects in 2018 and infrastructural challenges. GENEXI co-founder and CEO Alexey Zhelyaskov delivered a speech on the integration of blockchain and the real sector of economy.

Read the full article

Blockchain Leadership Summit | March 9th | Zurich, Switzerland

The Blockchain Leadership Summit took place on 9 March, 2018 in Zurich, Switzerland. It is widely regarded as one of the main conferences for experts and visionaries of the blockchain industry. Experts from the real sector, pioneers of the digital economy, investment bankers and officials from Switzerland, Liechtenstein, Kazakhstan, and Russia were among the attendees.

Read the full article

GENEXI at Blockchain Economic Forum 2018 in Singapore

GENEXI co-founder and CEO Alexey Zhelyaskov attended the Blockchain Economic Forum, held on 4-6 February, 2018 in Singapore. The Blockchain Economic Forum accentuated the growing influence of the crypto economy on global economic processes and facilitated a productive dialogue on the most crucial topics. The presence of Vincente Fox, the former President of Mexico, should be noted.

Read the full article

GENEXI took part in the FINWISE SUMMIT 2018 in Macau

The Finwise Summit was held on 12-13 January, 2018 in Macau. It was aimed at encouraging interaction among the fintech industry participants and fostering further developments in this field. Over 3000 guests, hundreds of investment and fintech companies and roughly 60 blockchain projects attended the summit. UBS and a number of large Chinese banks were listed as major partners.

Read the full article

Join Genexi


We will contact you soon


Press about us